We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.50 | 0.70% | 1,651.00 | 1,651.00 | 1,652.00 | 1,656.00 | 1,637.00 | 1,650.50 | 4,661,376 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.80 | 68.01B |
From Apr 2019 to Apr 2024
By Adam Clark
Vectura Group PLC (VEC.LN) said Thursday that a U.K. court ruled against it in a patent dispute with GlaxoSmithKline PLC (GSK.LN).
The judgment related to a 2010 patent agreement between Vectura and GSK over Ellipta-branded products for lung disease and asthma.
Vectura said it was disappointed by the ruling and will consider its options, including seeking permission to appeal. Vectura said it doesn't believe the result will materially affect proceedings in the U.S. related to the same patent agreement.
Shares at 1242 GMT were down 1.60 pence, or 2.2%, at 71.05 pence.
Write to Adam Clark at adam.clark@dowjones.com
(END) Dow Jones Newswires
December 13, 2018 08:06 ET (13:06 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
